Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 15, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Oct 6, 2026Reported sale · Form 4ROBERT HERSHBERG · $125.0KOpen the filing ↗
- Oct 6, 2026Reported sale · Form 4Blake Borgeson · $242.0KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record95215 flagged findings
Reported transactions (Form 4)80since Feb 3, 2025 · and 21 other holdings
Corporate events (8-K)30since Oct 25, 2022
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
American pharmaceutical company
Source: Wikidata (CC0 1.0) · copied on Sep 3, 2026 · may not reflect recent changes.
The 25 most recent filings (of 952)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 15, 26424B5 ↗Securities offering new
- Oct 15, 268-K ↗Current report · Entered a material agreement new
- Oct 15, 26424B5 ↗Securities offering new
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Oct 6, 26Form 144 ↗Notice of proposed sale
- Oct 6, 26Form 144 ↗Notice of proposed sale
- Sep 21, 268-K ↗Current report · Entered a material agreement
- Sep 8, 26Form 144 ↗Notice of proposed sale
- Sep 2, 26Form 4 ↗Insider transaction
Notice of proposed sale · 4 Form 144 filingsshow all 4hide
- Sep 1, 26Form 144 ↗Notice of proposed sale
- Aug 21, 26Form 144 ↗Notice of proposed sale
- Aug 20, 26Form 144 ↗Notice of proposed sale
- Aug 19, 26Form 144 ↗Notice of proposed sale
- Aug 18, 26Form 144 ↗Notice of proposed sale
- Aug 18, 26Form 4 ↗Insider transaction
Notice of proposed sale · 3 Form 144 filingsshow all 3hide
- Aug 13, 26Form 144 ↗Notice of proposed sale
- Aug 12, 26Form 144 ↗Notice of proposed sale
- Aug 10, 26Form 144 ↗Notice of proposed sale
952 filings on record, the oldest from Feb 22, 21.
Listing the 25 most recent filings of the 952 on record.
11714
- Oct 15, 26Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Sep 21, 26Entered a material agreement8-K 1.01 ↗
3 senior executive changes2025 – 2026show all 3hide
- Apr 30, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Mar 25, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Nov 5, 25A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Aug 29, 25Sold unregistered shares+2 more in the same filing8-K/A 3.02 ↗
- Jul 8, 25Sold unregistered shares+3 more in the same filing8-K 3.02 ↗
- Jun 10, 25Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Mar 18, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Dec 3, 24A senior executive left or was appointed8-K 5.02 ↗
- Nov 26, 24Sold unregistered shares8-K/A 3.02 ↗
- Nov 20, 24Completed an acquisition or disposal+4 more in the same filing8-K 2.01 ↗
- Nov 6, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Aug 8, 24Entered a material agreement+5 more in the same filing8-K 1.01 ↗
9 older filings not shown · The record reaches back to Dec 7, 21.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- MDC Capital Partners (Ventures) GP, LP1.4%Nov 20, 24SCHEDULE 13D/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.8.5%Jun 30, 26SCHEDULE 13G/A ↗2 earlier filings
- ARK Investment Management LLC7.3%Dec 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- STATE STREET CORPORATION6.6%Jun 30, 26SCHEDULE 13G ↗1 earlier filing
- Vanguard Portfolio Management6.0%Jun 30, 26SCHEDULE 13G ↗
- Vanguard Capital Management5.1%Jun 30, 26SCHEDULE 13G ↗
show 2 more holdershide
- BAILLIE GIFFORD & CO4.6%Dec 31, 25SCHEDULE 13G/A ↗2 earlier filings
- RA Capital Management, L.P.2.0%Dec 31, 24SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 6, Borgeson Blake filed notice of intent to sell up to $242K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $242K on Oct 6, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+9 more recent notices · 3 with a later sale
- Oct 6, 26Sell$125KROBERT HERSHBERG↗
- Oct 6, 26Sell$242KBlake Borgeson↗
- Sep 8, 26Sell$79KNajat KhanCEO and President↗
- Sep 1, 26Sell$100KBlake Borgeson↗
- Aug 4, 26Sell$98KBlake Borgeson↗
- Jul 7, 26Sell$159KBlake Borgeson↗
- Jun 18, 26Sell$13KNamandje Bumpus↗
- Jun 5, 26Sell$145KChristopher Gibson↗
- Jun 5, 26Sell$84KNajat KhanCEO and President↗
- Jun 3, 26Sell$16KNamandje Bumpus↗
- Jun 2, 26Sell$110KBlake Borgeson↗
- May 22, 26Sell$123KChristopher Gibson↗
There are 3 more transactions in this stretch.
Stock compensation, tax and giftsshow the 25 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 6, 26Compensation$56KROBERT HERSHBERG↗
- Oct 1, 26Compensationamount n/aDean Y Li↗
- Oct 1, 26Compensationamount n/aZavain Dar↗
- Sep 15, 26Tax$18KBen R TaylorChief Financial Officer↗
- Aug 17, 26Tax$79KBen R TaylorChief Financial Officer↗
- Aug 17, 26Tax$84KDavid HallettChief Scientific Officer↗
- Aug 17, 26Tax$254KNajat KhanCEO and President↗
- Jul 1, 26Compensationamount n/aDean Y Li↗
- Jul 1, 26Compensationamount n/aZavain Dar↗
- Jun 17, 26Compensationamount n/aNamandje Bumpus↗
- Jun 17, 26Compensationamount n/aDean Y Li↗
- Jun 17, 26Compensationamount n/aZavain Dar↗
- Jun 17, 26Compensationamount n/aElaine D Sun↗
- Jun 17, 26Compensationamount n/aFranziska Michor↗
- Jun 17, 26Compensationamount n/aROBERT HERSHBERG↗
- Jun 17, 26Compensationamount n/aBlake Borgeson↗
- Jun 15, 26Tax$17KBen R TaylorChief Financial Officer↗
- Jun 5, 26Otheramount n/aChristopher Gibson↗
- May 22, 26Otheramount n/aChristopher Gibson↗
- May 15, 26Tax$76KBen R TaylorChief Financial Officer↗
- May 15, 26Tax$69KChristopher Gibson↗
- May 15, 26Tax$81KDavid HallettChief Scientific Officer↗
- May 15, 26Tax$191KNajat KhanCEO and President↗
- May 7, 26Otheramount n/aChristopher Gibson↗
- May 7, 26Giftamount n/aChristopher Gibson↗
The full record holds 734 transactions and goes back to Jan 5, 22.
Its sector and its market
Recursion Pharmaceuticals, Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
- Ramsay Générale de Santé SA GDS
- Rani Therapeutics Holdings Inc. RANI
- Rapid Micro Biosystems, Inc. RPID
- Rapport Therapeutics Inc. RAPP
- Recordati Industria Chimica e Farmaceutica S.p.A. 0KBS
- Redcare Pharmacy N.V. RDC
- Regencell Bioscience Holdings Ltd. RGC
- Regeneron Pharmaceuticals, Inc. REGN
- Regentis Biomaterials Ltd. RGNT
- Regenxbio Inc. RGNX
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Recursion Pharmaceuticals, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Recursion Pharmaceuticals, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 952 documents on file, from Feb 22, 2021 to Oct 15, 2026.
- Company description
- Wikidata, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.